DropGenie Raises $5M Seed for Digital Microfluidics Gene-Editing Platform

DropGenie Closes $5 Million Seed Round

Montreal- and Boston-based biotechnology company DropGenie has raised $5 million in a seed round. The funding was disclosed on October 26, 2026.

What the Company Does

DropGenie is building a digital microfluidics platform that miniaturizes and automates non-viral gene-editing workflows. Its chip-based cartridge manipulates tiny droplets to deliver editing machinery directly into primary patient cells.

The platform is designed to enable low-volume, high-throughput cell engineering across several applications:

• Cell therapy
• Functional genomics
• AI-driven discovery

The technology aims to generate large volumes of standardized gene-editing data for pharmaceutical, biotech, and research customers.

Investor Group

The seed round includes participation from:

• Merck Global Health Innovation Fund
• Anges Quebec
• Real Ventures
• BDC Capital's Thrive Venture Fund
• Skeleton Key
• CQDM

The investor list spans corporate venture (Merck Global Health Innovation Fund), regional and early-stage funds (Anges Quebec, Real Ventures, Skeleton Key), a national venture fund (BDC Capital's Thrive Venture Fund), and a research-focused consortium (CQDM).

Why It Matters for the Sector

DropGenie sits at the intersection of two active areas in biotech: non-viral gene editing and automated, data-generating laboratory infrastructure. By miniaturizing editing workflows onto a chip-based cartridge, the company is targeting the throughput and standardization bottlenecks that constrain cell engineering at scale.

The emphasis on standardized gene-editing data is notable. As AI-driven discovery efforts in biotech depend on large, consistent datasets, a platform that can generate such data at low volume and high throughput addresses a recognized need among pharmaceutical, biotech, and research customers.

Round Summary

• Company: DropGenie
• Locations: Montreal and Boston
• Sector: Biotechnology — digital microfluidics for gene editing
• Round: Seed
• Amount: $5 million (USD)
• Date: October 26, 2026
• Investors: Merck Global Health Innovation Fund, Anges Quebec, Real Ventures, BDC Capital's Thrive Venture Fund, Skeleton Key, CQDM

Outlook

With seed capital in place, DropGenie is positioned to advance its digital microfluidics platform for non-viral gene-editing workflows. The company's chip-based cartridge approach — delivering editing machinery directly into primary patient cells — targets cell therapy, functional genomics, and AI-driven discovery applications, with a customer focus on pharmaceutical, biotech, and research organizations.